Provided by Tiger Trade Technology Pte. Ltd.

Biocryst Pharmaceuticals

9.34
-0.0400-0.43%
Post-market: 9.32-0.0200-0.21%19:34 EDT
Volume:1.85M
Turnover:17.35M
Market Cap:2.37B
PE:-5.27
High:9.49
Open:9.41
Low:9.30
Close:9.38
52wk High:11.22
52wk Low:6.00
Shares:254.11M
Float Shares:221.00M
Volume Ratio:0.76
T/O Rate:0.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7710
EPS(LYR):1.21
ROE:587.33%
ROA:42.62%
PB:-4.29
PE(LYR):7.72

Loading ...

Biocryst Pharmaceuticals - to Close Birmingham Discovery Center and End Internal Discovery Programs by End 2026

THOMSON REUTERS
·
Jun 29

Biocryst Pharmaceuticals - Completes Enrollment in Phase 3 Alpha-orbit Study for Navenibart

THOMSON REUTERS
·
Jun 29

Biocryst Pharmaceuticals - Improves 2026 Non-gaap Operating Expense Guidance to $420-$440 Mln

THOMSON REUTERS
·
Jun 29

Biocryst Pharmaceuticals Inc Fy2026 REV View $667.5 Mln

THOMSON REUTERS
·
Jun 29

How Investors Are Reacting To BioCryst (BCRX) Expanding Its HAE Prophylaxis Data Across Patient Groups

Simply Wall St.
·
Jun 15

BioCryst shareholders approve amended stock incentive plan, add 7 million shares

Reuters
·
Jun 13

BioCryst Pharmaceuticals' New Clinical Data Demonstrated Reduced Hereditary Angioedema Attacks With Orladeyo Treatment

MT Newswires Live
·
Jun 12

BioCryst says post hoc ALPHA-STAR analysis shows navenibart cuts HAE attack rates across patient subgroups

Reuters
·
Jun 12

BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of Hae Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting

THOMSON REUTERS
·
Jun 12

BioCryst grants 9 new hires options for 33,950 shares, RSUs for 80,650 shares under inducement plan

Reuters
·
Jun 10

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 10

BioCryst presents new ORLADEYO, navenibart hereditary angioedema trial data at EAACI 2026

Reuters
·
May 27

BioCryst director Amy E. McKee sells 11,180 shares worth $100,284.6

Reuters
·
May 20

BioCryst Chief Legal Officer Alane P. Barnes sells 62,500 shares for $596,250

Reuters
·
May 16

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings

Benzinga
·
May 08

BioCryst Pharmaceuticals Is Maintained at Buy by Needham

Dow Jones
·
May 07

BUZZ-U.S. STOCKS ON THE MOVE-Walt Disney, CVS, Uber

Reuters
·
May 06

Stock Track | BioCryst Pharmaceuticals Plunges 6.98% Pre-Market on Surprise Quarterly Loss

Stock Track
·
May 06

Earnings Flash (BCRX) BioCryst Pharmaceuticals Posts Q1 Net Loss $2.98 a Share, vs. FactSet Est of $0.04 EPS

MT Newswires Live
·
May 06

BioCryst Pharma Q1 Adj. EPS $0.14 Beats $0.05 Estimate, Sales $156.413M Beat $151.123M Estimate

Benzinga
·
May 06